LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Начало・Списък с акции・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

27.71 2.21

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

27.02

Максимум

27.79

Ключови измерители
By Trading Economics
Приходи	-547M -179M
Продажби	-515M 28M
Марж на печалбата	-643.397
Служители	609
EBITDA	-563M -166M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+31.28% upside

Дивиденти
By Dow Jones
Следващи печалби	25.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	771M 3B
Предишно отваряне	25.5
Предишно затваряне	27.71

Настроения в новините

By Acuity

94%

8 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

11.5 / 12.23 Подкрепа & съпротива

Arrowhead Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.09.2025 г., 23:37 ч. UTC

Горещи акции

Stocks to Watch: Oracle, Wearable Devices, GameStop

9.09.2025 г., 20:41 ч. UTC

Печалби

Oracle's Backlog Surges With Major Customer Deals in 1Q

9.09.2025 г., 20:30 ч. UTC

Печалби

GameStop 2Q Sales, Profit Rise

9.09.2025 г., 23:19 ч. UTC

Пазарно говорене

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9.09.2025 г., 21:35 ч. UTC

Печалби

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9.09.2025 г., 21:32 ч. UTC

Печалби

Oracle's Backlog Swells With Big Customer Deals -- Update

9.09.2025 г., 21:02 ч. UTC

Придобивния, сливания и поглъщания

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.09.2025 г., 20:33 ч. UTC

Печалби

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9.09.2025 г., 20:26 ч. UTC

Печалби

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9.09.2025 г., 20:23 ч. UTC

Печалби

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9.09.2025 г., 20:12 ч. UTC

Печалби

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9.09.2025 г., 20:10 ч. UTC

Печалби

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9.09.2025 г., 20:10 ч. UTC

Печалби

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9.09.2025 г., 20:09 ч. UTC

Печалби

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9.09.2025 г., 20:09 ч. UTC

Печалби

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9.09.2025 г., 20:08 ч. UTC

Печалби

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9.09.2025 г., 20:08 ч. UTC

Печалби

Oracle 1Q Operating Income Was $4.3 B >ORCL

9.09.2025 г., 20:08 ч. UTC

Печалби

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9.09.2025 г., 20:08 ч. UTC

Печалби

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9.09.2025 г., 20:07 ч. UTC

Печалби

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9.09.2025 г., 20:06 ч. UTC

Печалби

Oracle 1Q Software Revenue $5.72B >ORCL

9.09.2025 г., 20:06 ч. UTC

Печалби

Synopsys 3Q Adj EPS $3.39 >SNPS

9.09.2025 г., 20:06 ч. UTC

Печалби

Oracle 1Q Cloud Revenue $7.19B >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q Rev $14.93B >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q EPS $1.01 >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Synopsys 3Q EPS $1.50 >SNPS

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q Services Revenue $1.35B >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q Adj EPS $1.47 >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q Hardware Revenue $670M >ORCL

Сравнение с други в отрасъла

Ценова промяна

Arrowhead Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

31.28% нагоре

12-месечна прогноза

Среден 35.67 USD 31.28%

Висок 80 USD

Нисък 12 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Arrowhead Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Arrowhead Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

11.5 / 12.23Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Настроение

By Acuity

8 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.